Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr;201(1):58-63.
doi: 10.1111/bjh.18562. Epub 2022 Nov 16.

Antibody response to a third SARS-CoV-2 vaccine dose in recipients of an allogeneic haematopoietic cell transplantation

Andriyana K Bankova  1 , Chloé Pasin  2   3 , Alice Huang  1 , Caroline Cicin-Sain  1 , Selina Epp  2 , Annette Audige  2 , Nicolas J Mueller  3 , Jakob Nilsson  4 , Oliver Vilinovszki  1   5 , Gayathri Nair  1 , Nathan Wolfensberger  1 , Philipp Hockl  1 , Urs Schanz  1 , Alexandra Trkola  2 , Roger Kouyos  2   3 , Barbara Hasse  3 , Annelies S Zinkernagel  3 , Markus G Manz  1 , Irene A Abela  2   3 , Antonia M S Müller  1   6
Affiliations
Free article

Antibody response to a third SARS-CoV-2 vaccine dose in recipients of an allogeneic haematopoietic cell transplantation

Andriyana K Bankova et al. Br J Haematol. 2023 Apr.
Free article

Abstract

Allogeneic haematopoietic cell transplantation (allo-HCT) recipients show impaired antibody (Ab) response to a standard two-dose vaccination against severe acute respiratory syndrome coronavirus-2 and currently a third dose is recommended as part of the primary vaccination regimen. By assessing Ab titres 1 month after a third mRNA vaccine dose in 74 allo-HCT recipients we show sufficient neutralisation activity in 77% of the patients. Discontinuation of immunosuppression before the third vaccine led to serological responses in 50% of low responders to two vaccinations. Identifying factors that might contribute to better vaccine responses in allo-HCT recipients is critical to optimise current vaccination strategies.

Keywords: allogeneic haematopoietic cell transplantation; severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2); vaccine response.

PubMed Disclaimer

References

REFERENCES

    1. Ljungman P, de la Camara R, Mikulska M, Tridello G, Aguado B, Zahrani MA, et al. COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey. Leukemia. 2021;35(10):2885-94.
    1. Sharma A, Bhatt NS, St Martin A, Abid MB, Bloomquist J, Chemaly RF, et al. Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study. Lancet Haematol. 2021;8(3):e185-e93.
    1. Huang A, Cicin-Sain C, Pasin C, Epp S, Audige A, Muller NJ, et al. Antibody response to SARS-CoV-2 vaccination in patients following allogeneic hematopoietic cell transplantation. Transplant Cell Ther. 2022;28:214.e1-214.e11.
    1. Mamez AC, Pradier A, Giannotti F, Petitpas A, Urdiola MF, Vu DL, et al. Antibody responses to SARS-CoV2 vaccination in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2021;56(12):3094-6.
    1. Ram R, Hagin D, Kikozashvilli N, Freund T, Amit O, Bar-On Y, et al. Safety and immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in patients after allogeneic HCT or CD19-based CART therapy-a single-center prospective cohort study. Transplant Cell Ther. 2021;27(9):788-94.

Publication types